UBS AM’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.45M | Buy |
34,025
+17,841
| +110% | +$1.02M | ﹤0.01% | 1941 |
|
|
2025
Q4 | $684K | Buy |
+16,184
| New | +$906K | ﹤0.01% | 2254 |
|
|
2023
Q3 | – | Sell |
-13,911
| Closed | -$147K | – | 2655 |
|
|
2023
Q2 | $147K | Hold |
13,911
| – | – | ﹤0.01% | 2606 |
|
|
2023
Q1 | $147K | Buy |
13,911
+2,766
| +25% | +$83.7K | ﹤0.01% | 2606 |
|
|
2022
Q4 | $378K | Hold |
11,145
| – | – | ﹤0.01% | 2281 |
|
|
2022
Q3 | $535K | Sell |
11,145
-1,848
| -14% | -$110K | ﹤0.01% | 2322 |
|
|
2022
Q2 | $741K | Sell |
12,993
-7,272
| -36% | -$459K | ﹤0.01% | 2118 |
|
|
2022
Q1 | $1.64M | Buy |
20,265
+2,828
| +16% | +$419K | ﹤0.01% | 1892 |
|
|
2021
Q4 | $3.53M | Buy |
17,437
+116
| +0.7% | +$25.2K | ﹤0.01% | 1571 |
|
|
2021
Q3 | $4.67M | Hold |
17,321
| – | – | ﹤0.01% | 1378 |
|
|
2021
Q2 | $4.46M | Buy |
17,321
+482
| +3% | +$133K | ﹤0.01% | 1428 |
|
|
2021
Q1 | $5.05M | Sell |
16,839
-101
| -0.6% | -$31.4K | ﹤0.01% | 1328 |
|
|
2020
Q4 | $4.32M | Buy |
16,940
+2,349
| +16% | +$607K | ﹤0.01% | 1360 |
|
|
2020
Q3 | $3.63M | Buy |
14,591
+314
| +2% | +$98.8K | ﹤0.01% | 1287 |
|
|
2020
Q2 | $4.96M | Sell |
14,277
-2,151
| -13% | -$671K | ﹤0.01% | 1120 |
|
|
2020
Q1 | $4.4M | Buy |
16,428
+1,219
| +8% | +$377K | ﹤0.01% | 1086 |
|
|
2019
Q4 | $4.92M | Sell |
15,209
-16,141
| -51% | -$4.68M | ﹤0.01% | 1195 |
|
|
2019
Q3 | $8.57M | Sell |
31,350
-13,287
| -30% | -$4.87M | 0.01% | 1005 |
|
|
2019
Q2 | $23.8M | Sell |
44,637
-4,579
| -9% | -$2.3M | 0.02% | 719 |
|
|
2019
Q1 | $24.8M | Buy |
49,216
+401
| +0.8% | +$238K | 0.02% | 691 |
|
|
2018
Q4 | $24.1M | Buy |
48,815
+5,542
| +13% | +$3.35M | 0.02% | 660 |
|
|
2018
Q3 | $39.6M | Buy |
43,273
+4,046
| +10% | +$3.45M | 0.03% | 570 |
|
|
2018
Q2 | $28.7M | Buy |
39,227
+24,005
| +158% | +$27.7M | 0.02% | 677 |
|
|
2018
Q1 | $24.3M | Buy |
15,222
+496
| +3% | +$639K | 0.02% | 719 |
|
|
2017
Q4 | $13.2M | Sell |
14,726
-12,804
| -47% | -$7.57M | 0.01% | 846 |
|
|
2017
Q3 | $9.91M | Buy |
27,530
+6,869
| +33% | +$2.15M | 0.01% | 902 |
|
|
2017
Q2 | $6.06M | Buy |
20,661
+14,051
| +213% | +$4.06M | 0.01% | 994 |
|
|
2017
Q1 | $2.33M | Buy |
6,610
+286
| +5% | +$64.3K | ﹤0.01% | 1285 |
|
|
2016
Q4 | $1.16M | Sell |
6,324
-1,750
| -22% | -$356K | ﹤0.01% | 1496 |
|
|
2016
Q3 | $2.08M | Buy |
8,074
+332
| +4% | +$85.5K | ﹤0.01% | 1362 |
|
|
2016
Q2 | $1.65M | Sell |
7,742
-1,076
| -12% | -$241K | ﹤0.01% | 1427 |
|
|
2016
Q1 | $1.82M | Buy |
8,818
+2,053
| +30% | +$394K | ﹤0.01% | 1405 |
|
|
2015
Q4 | $1.71M | Sell |
6,765
-3,757
| -36% | -$773K | ﹤0.01% | 1505 |
|
|
2015
Q3 | $1.73M | Buy |
10,522
+5,382
| +105% | +$952K | ﹤0.01% | 1504 |
|
|
2015
Q2 | $965K | Buy |
5,140
+660
| +15% | +$114K | ﹤0.01% | 1694 |
|
|
2015
Q1 | $739K | Buy |
4,480
+167
| +4% | +$34.3K | ﹤0.01% | 1763 |
|
|
2014
Q4 | $1M | Sell |
4,313
-11,795
| -73% | -$2.52M | ﹤0.01% | 1589 |
|
|
2014
Q3 | $2.92M | Sell |
16,108
-507
| -3% | -$97K | ﹤0.01% | 1176 |
|
|
2014
Q2 | $3.19M | Sell |
16,615
-513
| -3% | -$90.7K | ﹤0.01% | 1157 |
|
|
2014
Q1 | $3.11M | Sell |
17,128
-1,363
| -7% | -$270K | ﹤0.01% | 1164 |
|
|
2013
Q4 | $3.15M | Sell |
18,491
-16,549
| -47% | -$2.67M | ﹤0.01% | 1127 |
|
|
2013
Q3 | $5.49M | Sell |
35,040
-16,481
| -32% | -$3.05M | 0.01% | 962 |
|
|
2013
Q2 | $8.93M | Buy |
+51,521
| New | +$7.9M | 0.01% | 801 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
UBS AM's NKTR Position: Q1 2026 in Review
UBS AM increased its Nektar Therapeutics (NKTR) stake by 110% in Q1 2026, buying an estimated $1.02M and bringing the position to 34,025 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1941.
UBS AM first reported a position in NKTR in Q2 2013 and has held it in 43 quarters since. The position peaked at $39.6M in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- UBS AM held 34,025 shares of Nektar Therapeutics worth $2.45M as of Q1 2026.
- UBS AM bought 17,841 Nektar Therapeutics shares in Q1 2026, an estimated $1.02M.
- Nektar Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #1941 holding.
- UBS AM first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 43 quarters since.
- UBS AM's Nektar Therapeutics position peaked at $39.6M in Q3 2018.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.